Synairgen plc (LON:SNG) had its price objective lowered by N+1 Singer from GBX 47 ($0.61) to GBX 46 ($0.60) in a research report report published on Thursday. The brokerage currently has a buy rating on the stock.
Separately, FinnCap reaffirmed a corporate rating and issued a GBX 137 ($1.79) target price on shares of Synairgen plc in a research report on Thursday, September 22nd.
Synairgen plc (LON:SNG) opened at 32.50 on Thursday. Synairgen plc has a one year low of GBX 19.00 and a one year high of GBX 38.00. The stock has a 50 day moving average price of GBX 34.30 and a 200-day moving average price of GBX 30.49. The firm’s market capitalization is GBX 29.69 million.
About Synairgen plc
Synairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls).
Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with MarketBeat.com's FREE daily email newsletter.